Potent Dual Inhibitors of TORC1 and TORC2 Complexes (KU-0063794 and KU-0068650) Demonstrate In Vitro and Ex Vivo Anti-Keloid Scar Activity  by Syed, Farhatullah et al.
Potent Dual Inhibitors of TORC1 and TORC2
Complexes (KU-0063794 and KU-0068650)
Demonstrate In Vitro and Ex Vivo Anti-Keloid
Scar Activity
Farhatullah Syed1,2, Hitesh J. Sanganee3, Ashwani Bahl3 and Ardeshir Bayat1,2,4
Mammalian target of rapamycin (mTOR) is essential in controlling several cellular functions. This pathway is
dysregulated in keloid disease (KD). KD is a common fibroproliferative dermal lesion with an ill-defined
treatment strategy. KD demonstrates excessive matrix deposition, angiogenesis, and inflammatory cell infiltration.
In KD, both total and phosphorylated forms of mTOR and p70S6K(Thr421/Ser424) are upregulated. Therefore, the
aim of this study was to investigate adenosine triphosphate–competitive inhibitors of mTOR kinase previously
unreported in keloid and their comparative efficacy with Rapamycin. Here, we present two mTOR kinase
inhibitors, KU-0063794 and KU-0068650, that target both mTORC1 and mTORC2 signaling. Treatment with either
KU-0063794 or KU-0068650 resulted in complete suppression of Akt, mTORC1, and mTORC2, and inhibition of
keloid cell spreading, proliferation, migration, and invasive properties at a very low concentration (2.5mmol l 1).
Both KU-0063794 and KU-0068650 significantly (Po0.05) inhibited cell cycle regulation and HIF1-a expression
compared with that achieved with Rapamycin alone. In addition, both compounds induced shrinkage and growth
arrest in KD, associated with the inhibition of angiogenesis, induction of apoptosis, and reduction in keloid
phenotype–associated markers. In contrast, Rapamycin induced minimal antitumor activity. In conclusion, potent
dual mTORC1 and mTORC2 inhibitors display therapeutic potential for the treatment of KD.
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INTRODUCTION
The mammalian target of Rapamycin (mTOR) is a 289-kDa
serine–threonine kinase that regulates cellular activity (Dazert
and Hall, 2011). mTOR kinases form two distinct multiprotein
complexes mTORC1 and mTORC2. Inhibition of mTORC1
alone by rapalogs leads to enhanced activation of PI3K axis by
the mTOR-S6K-IRS1-negative feedback loop (Bracho-Valdes
et al., 2011). mTORC2 phosphorylates Akt on Ser473,
increasing its enzyme activity up to 10-fold (Chresta et al.,
2010). Activated Akt regulates many cellular functions. Thus,
mTORC2 is an attractive target in cancer (Sini et al., 2010;
Sparks and Guertin, 2010).
Keloid disease (KD) is a fibroproliferative lesion character-
ized by excessive deposition of extracellular matrix (ECM)
such as collagen (Shih et al., 2010), fibronectin (FN), and a-
smooth muscle actin (a-SMA) (Supplementary Figure S1a
online) (Ong et al., 2007). KD fibroblasts possess cancer-like
properties (Vincent et al., 2007), with overexpression of
cytokines and increased angiogenesis (Shih et al., 2010)
(Supplementary Figure S1b online). KD infiltrates the sur-
rounding tissue with up to 80% recurrence post excision (Mall
et al., 2002). Many treatment modalities exist, but they fail to
prevent KD recurrence (Patel and Lawrence Cervino, 2010),
hence the urgency for effective treatment options. mTOR is a
regulator of collagen expression in dermal fibroblasts shown
by the inhibition of ECM deposition with Rapamycin
(Shegogue and Trojanowska, 2004). The PI3K/Akt/mTOR
pathway leads to the overproduction of ECM in KD, and
targeting of the mTOR pathway is a potential therapeutic
approach in eradicating keloids (Lim et al., 2003; Zhang et al.,
2006; Ong et al., 2007). We hypothesized that dual mTORC1
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and mTORC2 inhibition provides superior inhibition of Akt
signaling and anti-angiogenic activity. Unlike Rapamycin,
which inhibits mTORC1 alone (Benjamin et al., 2011), here
we demonstrate that both KU-0063794 and KU-0068650
(referred to collectively as AstraZeneca (AZ) compounds) are
highly selective adenosine triphosphate-competitive inhibitors
(Garcia-Martinez et al., 2009) of mTOR kinase activity, with
no toxicity in vivo (Malagu et al., 2009; Janes et al., 2010;
Dormond-Meuwly et al., 2011), similar in mechanism of
action to AZD8055 (Chresta et al., 2010; Sini et al., 2010).
Therefore, we investigated (i) the baseline cellular levels of
mTOR, p70S6K, and their activated forms between KD and
extra-lesional tissue (ELT) obtained from the same patient, (ii)
the effect of both AZ compounds on KD growth and ECM
deposition in vitro and ex vivo, and (iii) differences between
KU-0063794 and KU-0068650 to a well-recognized mTOR
inhibitor Rapamycin.
RESULTS
Overexpression of Total and Phosphorylated forms of mTOR and
p70S6K
There was a differential expression of mTOR and p70S6K and
their phosphorylated forms in KD compared with ELT and
extra-lesional fibroblasts (ELFs) (Supplementary Figure S1c
online). Total and phosphorylated forms of mTOR showed
high expression of both forms in KD compared with ELT
(Figure 1a). The average total immunoreactivity using In-Cell
Western Blotting showed a significant (*Po0.02) increase in
mTOR, p-mTOR, p70S6K, and phospho-p70S6K(Thr421/
Ser424) in keloid fibroblasts (KFs) compared with ELFs
(Figure 1b and c). Thus, mTOR is active in KD.
Concentration-dependent effect of KU-0063794 and
KU-0068650 on PI3K/AKT/mTOR intracellular signaling
The inhibitory potential of both AZ compounds was compared
with Rapamycin, an allosteric mTORC1 inhibitor (Benjamin
et al., 2011), in intracellular PI3K/Akt/mTOR signaling of KFs
and ELFs. Both AZ compounds demonstrated a dose-dependent,
significant (Po0.01) decrease in pAkt-S473. mTORC1
downstream substrates, 4E-BP1, and S6 ribosomal protein
were efficiently (Po0.01) dephosphorylated. Both AZ
compounds neither inhibited phosphorylated mitogen-
activated protein kinase nor pAkt-T308 at a low concentration
(2.5mmol l1). Furthermore, both AZ compounds reduced
(Po0.05) phosphorylation of GSK3b, a critical downstream
element of the PI3kinase/Akt and HIF1-a (Po0.01).
Rapamycin (20mmol l1) significantly reduced pAkt-T308, but
had no effect on pAkt-S473 (Figure 1d). Both AZ compounds did
not cause inhibition of PI3K/Akt/mTOR signaling in ELFs at
2.5mmol l1 (Supplementary Figure S2 online). This discre-
pancy could be due to reduced expression of mTOR and
p-mTOR in ELFs compared with KFs. Therefore, both AZ
compounds appear specific in the inhibition of pAkt-S473.
Dissociation of mTORC1 and mTORC2 complexes by
KU-0063794 and KU-0068650
Both AZ compounds showed a significant (Pp0.01) reduction
of p-mTOR, Rictor, and Raptor immunoreactivity (Figure 1e).
In contrast, Rapamycin only reduced p-mTOR and Raptor
immunoreactivity (Po0.05). To confirm the effect on the
mTORC1 and mTORC2 complex observed in KFs, we
performed an immunoprecipitation assay. Predictably, both
AZ compounds inhibited the association of mTORC1 with
Raptor and mTORC2 with Rictor, whereas Rapamycin failed
to show mTORC2 inhibition in KFs (Figure 1f). These results
demonstrate that both AZ compounds inhibit mTORC1 and
mTORC2 inhibitors as described previously with AZD8055
(Chresta et al., 2010) and P529 (Xue et al., 2008).
KU-0063794 and KU-0068650 reduced viability/metabolic
activity and inhibited cell spreading, attachment, and
proliferation in a concentration-dependent manner
The effect of KU-0063794 and KU-0068650 on cell behavior
was compared with Rapamycin with the water-soluble tetra-
zolium salt-1 (WST-1) assay using a range of concentrations.
Treatment with different concentrations resulted in significant
(Pp0.03) reduction in cell viability/metabolic activity in a
dose-dependent manner. However, both AZ compounds had
a significantly (Po0.03) higher effect on KFs compared with
ELFs. In contrast, Rapamycin showed a similar effect on KFs
and ELFs. After compound removal, the effect of Rapamycin
recovered in both KFs (Figure 2a) and ELFs (Figure 2b)
compared with both AZ compounds.
The cell growth inhibition displayed by both AZ com-
pounds was evaluated using a label-free real-time cell analysis
(RTCA) on a microelectronic sensor array (Syed et al.,
2012a,b). Both AZ compounds (Po0.02) and Rapamycin
significantly (Po0.05) inhibited cell spreading, attachment,
and proliferation in a time- and dose-dependent manner in
KFs. Similar dose-dependent and time-dependent inhibitions
were also seen in ELFs. In addition, both AZ compounds had a
sustained effect on KFs and ELFs seen by the recovery of cells
after removal of the inhibitors at 24 hours. When treatment
with all three compounds was complete, KFs and ELFs were
not able to recover within 26–30 hours compared with the
vehicle-treated group. Importantly, in the KU-0068650-treated
group, the average cell index was reduced further, suggesting
that the effect was sustained in this group. However, in the
KU-0063794- and Rapamycin-treated groups, there was an
increase in the average cell index in KFs (Figure 2c and
Supplementary Figure S3a online) compared with ELFs
(Supplementary Figure S3b and c online). Compared with
Rapamycin (20mmol l1), KU-0063794 and KU-0068650
were highly effective even at a very low concentration
(2.5mmol l 1). Taken together, both AZ compounds signifi-
cantly (Po0.05) decreased KF and ELF proliferation in a
concentration- and time-dependent manner.
KU-0063794 and KU-0068650 strongly inhibited the migration
and invasion properties of KFs and induced apoptosis in a
concentration-dependent manner
Cell growth inhibition properties of both AZ compounds were
evaluated using an in vitro collagen-coated two-dimensional
migration assay. Treatment with both AZ compounds signifi-
cantly (Po0.01) reduced the migration of KFs compared with
the Rapamycin-treated group, in a concentration-dependent
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Figure 1. Inhibition of intracellular signaling in keloid fibroblast (KF) by both KU-0063794 and KU-0068650. (a) Differential expression of mammalian target of
rapamycin (mTOR) and phosphor-mTOR (p-mTOR) (n¼6). (b) Differential expression of mTOR signaling in KFs and extra-lesional fibroblasts (ELFs) using In-Cell
Western Blotting (ICWB) (n¼11). (c) ICWB average immunoreactivity from (b). (d) ICWB average immunoreactivity of KF (n¼11) induced mTOR inhibitors,
normalized to b-actin. (e) Both KU-0063794 and KU-0068650 inhibit mTORC1 and mTORC2 in primary KFs. Bar graphs represent the quantification of average
protein expression in different treatments from three independent ICWB experiments (n¼ 6). (f) Co-immunoprecipitation for mTOR with raptor and Rictor to assess
TORC1 and TORC2 complex inhibition by both the compounds (n¼ 11). The data presented here are the means±SEM of triplicate experiments performed.
**Po0.05, *Pp0.01 indicate significant difference in the treated group compared with the DMSO control group. AKT, also known as protein kinase B (PKB); 4E-
BP1, eukaryotic initiation factor 4 E-binding protein-1; GSK3b, glycogen synthase kinase-3; HIF-1a, hypoxia-inducible factor-1alpha; IP, immunoprecipitation;
MAPK, mitogen-activated protein kinase; p-MAPK, phosphorylated mitogen-activated protein kinase; Raptor, regulatory associated protein of mTOR; Rictor,
rapamycin-insensitive companion of mTOR.
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manner. Rapamycin also reduced the migration of KFs
significantly (Po0.05), but at a higher concentration
(20mmol l1) compared with the vehicle control. However,
migration inhibitory effect by both AZ compounds was low in
ELFs compared with KFs (Figure 3a and b).
An Oris three-dimensional basement membrane extract
invasion and detection assay was used to assess the anti-
invasive properties of both AZ compounds. KFs showed a high
level of invasion (Po0.01) compared with ELFs. Treatment
with both AZ compounds significantly (Po0.01) reduced
the invasive properties of KFs at 48 hours post treatment,
whereas Rapamycin showed significant (Po0.05) inhibition
of KF invasion with a low efficacy compared with
both AZ compounds (Figure 3c and d). These results suggest
that both AZ inhibitors have potential anti-invasive
properties.
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Figure 2. Role of mammalian target of rapamycin (mTOR) inhibitors on keloid cell viability/metabolic activity by water-soluble tetrazolium salt-1 (WST-1),
cell adhesion, spreading, and proliferation by real-time cell analysis (RTCA) on microelectronic sensor arrays. (a) WST-1 assay was performed 24 hours post
treatment with different mTOR inhibitors, for viability/metabolic activity (keloid fibroblast (KF): n¼ 8). (b) WST-1 assay for extra-lesional fibroblasts (n¼5).
(c) Quantitative analysis of RTCA average cell index of KFs (n¼ 9). Primary KFs were seeded on 96-well E-plate (1 104 cells per well) and cells were treated with
different mTOR inhibitor concentrations. Cell index (CI) on RTCA was recorded every 15 minutes. **Po0.04, *Pp0.01 indicate significant difference compared
with the DMSO control group. The data expressed are an average means±SEM from four independent experiments.
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On the basis of the WST-1 and RTCA results, it was
hypothesized that both AZ compounds may achieve their
inhibitory effect via apoptosis or cellular necrosis. Indeed,
both compounds induced significant apoptosis, as there was
an increase in Annexin V–positive cells (Po0.05) at 24 hours
post treatment, compared with Rapamycin (5mmol l 1) and
control group, in a concentration-dependent manner.
However, higher doses (20mmol l 1) of Rapamycin also
caused significant (Po0.05) apoptosis. Importantly, both AZ
compounds caused a reduced level of apoptosis in ELFs
compared with KFs (Supplementary Figure S4a and b online).
Thus, both AZ compounds inhibited cellular activity by
inducing apoptosis.
KU-0063794 and KU-0068650 downregulated ECM, cell cycle
markers, and decreased fibroblast proliferation in a
concentration-dependent manner
Both KU-0063794 and KU-0068650 significantly (Pp0.01)
downregulated the expression of collagen, FN, and a-SMA
compared with Rapamycin (Pp0.05) in a concentration-
dependent manner at messenger RNA in KFs (Figure 4a)
and protein levels in both KFs (Figure 4b and Supplementary
Figure S5a–c online) and ELFs (Supplementary Figure S5a–d
online). However, both AZ compounds inhibited ECM-
related proteins in ELFs, at higher concentrations compared
with KFs.
RTCA and WST-1 analyses demonstrated reduced levels of
cell proliferation and viability/metabolic activity. The expres-
sion levels of cell cycle proteins proliferating cell nuclear
antigen and Cyclin D were significant. Concentration-depen-
dent downregulation was observed in fibroblasts treated with
both AZ compounds at protein levels. However, Rapamycin
showed a significant (Po0.05) reduction in proliferating cell
nuclear antigen and Cyclin D expression at a higher concen-
tration compared with vehicle control (DMSO) in KFs and
ELFs. Both AZ compounds had a minimal effect on cell cycle
proteins at 2.5mmol l 1 in ELFs (Figure 4b and Supplementary
Figure S5d online).
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Figure 3. Differential effect of KU-0063794, KU-0068650, and Rapamycin on primary keloid fibroblast (KF) and extra-lesional fibroblast (ELF) migration
and invasion properties. (a) Fibroblast migration response toward the 2-mm migration zone, in an in vitro two-dimensional collagen assay. Representative
micrographs are shown from three independent experiments. (b) The average number of migrated fibroblasts in the migration zone with and without compounds.
*Po0.05, significant difference compared with the DMSO group. **Pp0.01, significant difference compared with the Rapamycin group. #Po0.05, significant
difference in KF migration compared with ELFs. (c) Fibroblasts’ invasive response toward the 2-mm invasion zone in an in vitro three-dimensional basement
membrane extract model. (d) The average number of invaded cells in the invasion zone. **Po0.01 indicates significant difference compared with primary ELFs.
*Po0.03 indicates significant difference in primary KFs compared with the DMSO group. #Po0.05 indicates significant difference in primary ELFs compared with
the DMSO group.
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Figure 4. Effect of KU-0063794 and KU-0068650 compounds compared to Rapamycin in in vitro and ex vivo keloid models. (a) Both KU-0063794 and KU-
0068650 inhibit the expression of collagen, fibronectin, and a-smooth muscle actin (a-SMA) at messenger RNA (mRNA) levels (keloid fibroblast (KF): n¼8). (b) In-
Cell Western Blotting analysis of the expression of ECM proteins, Cyclin D, and proliferating cell nuclear antigen (PCNA), 24 hours post treatment with different
mammalian target of rapamycin inhibitors (KF: n¼8). (c) Shrinkage of keloid organ culture (OC) after different compound treatments. Average weight of the keloid
OC (n¼ 10) at different time points are indicated in the bar graph. Four millimeter keloid explant biopsies were removed from the collagen gel matrix and its
weight was determined in triplicates. (d) In MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay both, KU-0063794 and KU-0068650 showed
much greater inhibitory effect on metabolic activity in keloid OC (n¼ 8) as compared with Rapamycin. *Po0.05, **Pp0.01 indicates significant difference
compared with the DMSO group.
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KU-0063794 and KU-0068650 induced apoptosis and
significantly reduced keloid volume and metabolic activity in
an ex vivo model
To evaluate the therapeutic potential of both AZ compounds
in KD, we used an ex vivo keloid organ culture (OC) model
(Bagabir et al., 2012) as described previously. Both AZ
compounds (10mmol l1) significantly (Pp0.02) induced the
shrinkage and reduced the keloid OC volume compared with
the vehicle group on day 3. However, Rapamycin treatment
(20mmol l1) also significantly (Po0.05) decreased the
average weight of the keloid OC at week 1 compared with
the vehicle group (Figure 4c and Supplementary Figure S6a
online).
Both AZ compounds (2.5mmol l1) and Rapamycin signifi-
cantly (Po0.05) reduced metabolic activity from day 3 to
week 4 as compared with the vehicle group evidenced by
an MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay (Figure 4d). Furthermore, both AZ compounds
significantly (Po0.02) increased apoptosis on day 3 in situ
compared with the Rapamycin-treated group. However,
Rapamycin did not cause any significant apoptosis until week
1 post treatment, compared with the vehicle group. At week 4,
55–65% TUNEL-positive cells were observed in both the AZ
inhibitor (10mmol l1)–treated groups, whereas the Rapamy-
cin (20mmol l 1)-treated group showed only 35–40% TUNEL-
positive cells (Figure 5a and b). Thus, both AZ compounds
caused shrinkage of keloid tissue in an ex vivo model on day 3
post treatment, plus they reduced metabolic activity and
induced massive apoptosis at 2.5mmol l1 compared with
Rapamycin (20mmol l1) in a keloid ex vivo model.
Tissue morphological analysis revealed reduced cellularity/
inflammation and angiogenesis by KU-0063794 and
KU-0068650
In hematoxylin and eosin–stained tissue sections, histological
changes were evaluated in the epidermis, papillary dermis,
and reticular dermis. Up to day 3, the overall tissue archi-
tecture was well preserved in the Rapamycin-treated group,
whereas at week 1 both AZ compound–treated groups showed
reduced cellularity and thinning of the stratum granulosum
and papillary dermis. Both KU-0063794- and KU-0068650-
treated groups showed that the epidermis was completely
detached from week 1 to week 4 of treatment and exhibited
more intense tissue damage, characterized by keloid cell loss,
increased number of cells with pyknotic nuclei, and reduced
fibrosis (thick collagen bundles). In contrast, Rapamycin
showed minimal effect on keloid OC despite a higher
concentration (20mmol l 1). However, at week 4, Rapamy-
cin-treated explants showed detachment of the epidermis,
with increased number of cells showing pyknotic nuclei,
although the overall structure was better preserved compared
with AZ compound–treated keloid tissue. Both AZ compounds
also induced a noticeable decrease in the hyalinized collagen
bundles in the keloid tissue model at week 1 through to week
4 (Supplementary Figure S6b online).
Keloid tissue shows increased blood vessel density com-
pared with extra-lesional skin (Supplementary Figure S1b
online). Therefore, we examined the anti-angiogenic and
anti-vascular properties of both AZ compounds. Indeed, these
showed a drastic reduction in the number of CD31þ ve
(endothelial cell marker) (Figure 5c) and CD34þ ve (a micro-
vascular endothelial cell marker) cells (Figure 5d) in the
papillary and reticular dermis at week 1 up to week 4. In
contrast, Rapamycin showed a noticeable reduction in both
anti-CD31 and anti-CD34 expression only at week 4. The
above findings suggest that significant shrinkage of keloid
tissue in both AZ compound–treated groups may be due to a
combination of anti-proliferative and apoptotic effects along
with a compound-related anti-angiogenic and anti-vascular
effect.
Inhibition of PI3K-Akt-mTOR signaling in keloid OC model by
KU-0063794 and KU-0068650
To evaluate the ex vivo effects of both AZ compounds
compared with Rapamycin, on intracellular signaling in situ,
tissue was analyzed with immunohistochemistry post treat-
ment. In both KU-0063794- and KU-0068650-treated groups,
the expression of pAkt-S473 (Supplementary Figure S7a
online), p-mTOR (Supplementary Figure S7b online), and
pS6 (Supplementary Figure S7c online) was reduced at
week 1 compared with the Rapamycin-treated group, whereas
in the Rapamycin-treated group pAkt-S473, p-mTOR, and
pS6 reduced at week 4.
KU-0063794 and KU-0068650 suppressed pro-collagen, FN
biosynthesis, and a-SMA expression in the keloid OC model
Finally, we elucidated the potential anti-fibrotic effect of both
KU-0063794 and KU-0068650 in keloid OC in situ. As
expected, treatment with both AZ inhibitors reduced the
immunoreactivity of pro-collagen I at week 1 post treatment
compared with the Rapamycin-treated group (Supplementary
Figure S8 online). Similarly, FN was reduced by both AZ
compounds on day 3 and week 1 compared with the
Rapamycin-treated group (Supplementary Figure S9a online).
We also assessed for the expression of a-SMA, which showed
a significant reduction by both the AZ compounds at week 1
up to week 4 (Supplementary Figure S9b online). Never-
theless, Rapamycin also suppressed the expression level of
pro-collagen, FN, and a-SMA at week 1 up to week 4 at a
higher concentration compared with the vehicle group. In
summary, both AZ compounds caused a significant reduction
of ECM-related proteins in keloid tissue compared with
Rapamycin.
DISCUSSION
Using in vitro and ex vivo experiments, here we demonstrate
two compounds, previously unreported in keloid, KU-
0063794 and KU-0068650, that show promising anti-fibrotic
activity. Both compounds are not only potent but also
selective mTORC1 and mTORC2 inhibitors compared with
Rapamycin.
Both AZ compounds attenuated Akt phosphorylation at
specific Ser473 and significantly inhibited mTORC1 and
mTORC2 complexes, whereas Rapamycin only inhibited the
mTORC1 complex. Consistent with our results, recently, KU-
0063794 (Garcia-Martinez et al., 2009), AZD8055 (Chresta
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et al., 2010; Marshall et al., 2011), Palomid 529 (Xue et al.,
2008), NVP-BEZ235 (Chapuis et al., 2010; Santiskulvong
et al., 2011), and WYE-125132 (Yu et al., 2010) have shown
similar inhibitory effect on mTORC1 and mTORC2. These
results demonstrate that these AZ compounds have a potential
anti-fibrotic effect. Both AZ compounds showed more
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Figure 5. Both KU-0063794 and KU-0068650 compounds induce apoptosis and deplete CD31 and CD34 þVe cells in keloid organ culture. (a) Representative
micrographs of TUNEL staining (red-nuclei and green–yellow TUNELþVe cells) (n¼ 8). Original magnification,  200. D, dermis; EP, epidermis. Arrows
indicate TUNELþVe cells. (b) % of TUNELþVe cells (n¼ 8). *Po0.05, **Po0.01 indicates significant difference compared with the DMSO control group.
(c) Representative micrographs of CD31þVe endothelial cells after different compound treatments (n¼8). Original magnification  100. Arrows indicate
CD31þVe cells. (d) Representative micrographs of CD34þVe microvascular endothelial cell marker after different compound treatments. Original magnification,
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effective inhibition of KF cell attachment, spreading,
proliferation, and caused cytotoxicity and reduced viability/
metabolic activity, as well as inhibited migration and invasion
properties at a low concentration (2.5mmol l1) compared
with Rapamycin (20mmol l1).
The cell inhibition properties were achieved partly by
suppressing proliferating cell nuclear antigen and cyclin D.
Reorganization of the actin cytoskeleton is a multistep process
and is an early event in cellular activity (Bracho-Valdes et al.,
2011). Both AZ compounds are potent inhibitors of mTORC2
(Jacinto et al., 2004; Bracho-Valdes et al., 2011), and this may
explain the inhibition of keloid cell attachment, spreading,
migration, and invasion. In the initial in vitro experiments,
using lactate dehydrogenase (cytotoxicity) assay, both AZ
compounds showed toxicity in keloid and ELFs. However,
the efficacy of both compounds was reduced in ELFs.
Importantly, the effect of both compounds was reversible
within 24 hours of drug removal in extra-lesional primary
fibroblasts but not in KFs (data not shown). From these results,
both AZ compounds are highly selective in inhibiting KF
activity.
Activation of the PI3K/Akt/mTOR pathway is important for
cell growth (Morgensztern and McLeod, 2005). As the
inhibition of PI3K/Akt/mTOR is known to induce apoptosis,
both AZ compounds showed severe apoptosis. In contrast,
Rapamycin displayed minimal apoptosis. The enhanced
ability of both AZ inhibitors to induce apoptosis may
explain why both compounds showed higher activity against
KF inhibition.
There is increasing evidence that the PI3K/Akt/mTOR
network has an important role in ECM regulation in fibrosis
(Ong et al., 2007; Dazert and Hall, 2011). Collagen, FN, and
a-SMA are proteins characteristic of the keloid phenotype
(Ong et al., 2007; Shih et al., 2010). Overall, these proteins
were selected to assess the effects on ECM production in
response to both AZ compounds in KD. Both KU-0063794
and KU-0068650 reduced collagen I, FN, and a-SMA
expression in vitro more significantly compared with
Rapamycin.
We further explored the antitumour activity of both
KU-0063794 and KU-0068650 in an ex vivo model
(Bagabir et al., 2012). Treating the keloid OC with both
inhibitors demonstrated histologically reduced cellularity,
inflammation, reduced hyalinized collagen bundles, and
reduced the average keloid volume in a shrinkage
assay. The effect of both compounds on PI3K/Akt/mTOR
signaling and angiogenesis showed a significant reduction
in p-mTOR and pAkt-S473 levels and significant anti-
angiogenic properties. Analysis of the effect of both
KU-0063794 and KU-0068650 on keloid-associated fibrotic
markers showed strong inhibition of collagen I, FN, and a-
SMA compared with Rapamycin, at low concentrations in an
ex vivo model.
KU-0063794 is a potent and highly specific mTOR inhibitor
for both mTORC1 and mTORC2, with an IC50 of 10 nM, but it
does not suppress the activity of 76 other protein kinases or
seven lipid kinases, including Class 1 PI3Ks at 1,000-fold
higher concentrations (Garcia-Martinez et al., 2009). In
addition, there is no literature available on the efficacy of
KU-0068650, which is similar in structure to both
KU-0063794 and AZD8055. Moreover, the active form of
mTOR (phospho-mTOR) is overexpressed in KD but not in
normal skin (Ong et al., 2007; Syed et al., 2012a).
Overall, both AZ compounds show significant inhibition of
primary KFs at very low concentrations. Indeed, a significant
effect by both AZ compounds was only seen in primary
normal skin fibroblasts at much higher concentrations, which
could have resulted in nonspecific effects on these cells. Thus,
the specificity of both AZ compounds is hitherto implied, as
both seem to act selectively on cells with active levels of
mTOR signaling.
Clinically adverse events have been demonstrated with the
use of mTORC1 inhibitor, Sirolimus, and its analogs (Xue
et al., 2008; Lewis et al., 2009; Jorge and David, 2011).
However, AZD8055 (a similar compound structurally to both
the AZ compounds used in this study) significantly reduced
the clonogenic growth of leukemic progenitors from primary
CD34þVe AML cells ex vivo. In contrast, exposure to
AZD8055 barely affected the clonogenic growth of normal
CD34þVe hematopoietic progenitors even at maximal
concentrations (Willems et al., 2012). As both AZ
compounds are from a similar family of compounds to
AZD8055, it is therefore plausible that both of these
compounds may not be toxic to normal cells. However, this
assertion remains to be formally tested in both of these AZ
compounds. Importantly, it remains to be determined whether
these compounds have a real measurable clinical effect on
disease tissue in an in vivo scenario before their safe potential
use in keloid patients.
Here, we propose a model for the mechanism of action
of these compounds on KD (Supplementary Figure S10
online). The PI3K/Akt/mTOR axis is an important target in
keloid pathogenesis, as dual inhibition of mTOR kinases by
both the AZ compounds inhibits cell proliferation, migra-
tion, and invasion, and causes severe apoptosis compared
with an allosteric mTORC1 inhibitor. Thus, both KU-
0063794 and KU-0068650 dual mTORC1 and mTORC2
inhibitors may prove to be innovative therapeutic candi-
dates for the treatment of keloid. Interestingly, both com-
pounds showed higher efficacy in keloid compared with
non-keloid derived cells. This could be due to active PI3K/
Akt/mTOR axis in KF compared with ELFs, suggesting that
both compounds are highly selective for PI3K/Akt/mTOR.
Another important observation was that KU-0068650 showed
a greater efficacy when compared with KU-0063794 at a
similar concentration (2.5mmol l1) in every assay, possibly
because of higher solubility, the presence of methyl groups,
and lower IC50 of KU-0068650 (Supplementary Table S2
online).
MATERIALS AND METHODS
Patient selection and recruitment
This study was conducted in accordance with the ethical principles of
Good Clinical Practice and the Declaration of Helsinki. This study
received ethical approval from the local research committee
(Manchester, UK), and all subjects gave full written, informed
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consent. Keloid tissues were harvested at the time of surgery from
patients confirmed to have clinical and pathological evidence of KD
(Syed et al., 2011; Bagabir et al., 2012) (Supplementary Figure S1c
online). Thirty-one keloid samples (out of 31 KD samples, 10 samples
were used for ex vivo study) (Supplementary Table S1 online) were
ethically consented (ethical approval was obtained from NHS Ethical
Committee).
Establishment of primary fibroblast cultures
Keloid and ELTs (Supplementary Figure S1c online) (ELT samples
were collected away from the keloid and importantly show no
lesional involvement in hematoxylin and eosin) were collected in
DMEM using a standard protocol to extract fibroblasts (Syed et al.,
2011, 2012a; Syed and Bayat, 2012a). In this study, passage 1 (p1) to
passage 4 (p4) cells were used.
KU-0063794, KU-0068650, rapamycin, and campothecin
compound regime
KU-0063794 and KU-0068650 (AstraZeneca, London, UK)
(Supplementary Table S2 online) (2.5; 10; 15; 20mmol l 1) were
compared with Rapamycin (Merck, Middlesex, UK) (5; 20mmol l 1).
Camptothecin (Sigma-Aldrich, Dorset, UK) at a concentration of
250 ng ml 1 was used as positive control for RTCA, lactate dehy-
drogenase, WST-1, and apoptotic assays.
High-throughput In-Cell Western Blotting and quantification
Fibroblasts were treated with various concentrations of KU-0063794,
KU-0068650, and Rapamycin, and In-Cell Western Blotting was
performed using an optimized protocol (Syed and Bayat, 2012a; Syed
et al., 2012a,b). For all antibodies used, see Supplementary Tables S3
and S4 online.
Immunoprecipitation and fluorescent western blotting
Primary KFs (2.5 105 cells per well) were grown in 24-well plates
for 24 hours. Cells were treated with compounds for 16 hours, and
then lysed with cell lysis buffer (1 radioimmunoprecipitation assay
buffer, Cell Signaling, Hertfordshire, UK). mTOR (1:75) antibody was
added and immune complexes were allowed to form by incubating
on a rotor overnight at 4 1C. AB50–55% slurry of protein G-Sephar-
ose (Sigma-Aldrich) was added and incubation was carried out for
3 hours at 4 1C. Immunoprecipitates were captured with protein
G-Sepharose, washed three times with cell lysis buffer, and
analyzed by immunoblotting. Protein concentrations were deter-
mined using the bicinchoninic acid protein assay reagent kit
(Thermo Scientific, Loughborough, UK). Equal amounts of protein
(100 mg per Lane) were separated by NuPAGE Novex Bis-Tris Gels
and transferred onto nitrocellulose membranes using iBlot Dry
blotting device (Invitrogen, Paisley, UK). Membranes were blocked
with blocking buffer (LI-COR, Cambridge, UK) for 30–45 minutes
at room temperature. The membranes were incubated with differ-
ent concentrations of primary antibodies (Supplementary Table S3
online) overnight at 4 1C. After incubation, the membranes were
washed and incubated with secondary antibodies (Supplementary
Table S4 online) for 1 hour 15 minutes at room temperature. The
membranes were washed and the signal was detected using the
Odyssey infrared imaging system (LI-COR); b-actin served as
loading control.
Label-free RTCA to determine the effect of different
concentrations of the compounds
We used a label-free RTCA on a microelectronic system to measure
cell attachment, spreading, and proliferation. The basic principle of
the RTCA system and the optimized protocol were described
previously in detailed (Xing et al., 2005; Syed and Bayat, 2012a;
Syed et al., 2012b).
In vitro two-dimensional migration assay
The assay was performed as described previously (Syed et al., 2012a;
Syed and Bayat, 2012b). Briefly, a Oris 96-well plate (Oris migration
assay kit, Cambridge Bioscience, Cambridge, UK) was coated with
9mg ml 1 rat-tail collagen (BD Bioscience, Oxford, UK) and
incubated for 30–45 minutes at 37 1C/5% CO2. After incubation, Oris
cell seeding stoppers were inserted according to the manufacturer’s
instructions. Serum-starved KFs and ELFs were pre-labeled with
PKH26 (Sigma-Aldrich) according to the manufacturer’s instructions.
A density of 2.5 105 cells per well was seeded in each well of the
Oris 96-well migration assay plates. The plate was then incubated
overnight at 37 1C/5% CO2. The next day, the cell seeding stoppers
were removed and 100ml of fresh medium was added with or without
different compounds as above; the plates were further incubated and
the cells were allowed to migrate for B30 hours in the migration
zone. Micrographs were captured using  4 magnification of inverted
microscopy (Olympus UK, Southend-on-Sea, UK). Cells in the
migration zone were counted from four independent experiments
and average migrated cells were plotted on the graphs.
In vitro three-dimensional invasion assay
Inhibition of the invasive capacity of KU-0063794, KU-0068650, and
Rapamycin was tested using basement membrane extract in vitro in
three-dimensional invasion assay (Oris Invasion and detection assay
kit, Cambridge Bioscience) as described previously (Syed and Bayat,
2012a; Syed et al., 2012a). Briefly, serum-starved cells at a density of
2.5 105 cells per well were seeded in Oris invasion assay plates and
allowed to attach for 8–12 hours at 371C/5% CO2; after cell attach-
ment, the stoppers were removed from the wells and cells were
washed once with phosphate-buffered saline and 40ml of basement
membrane extract was added to the cells. The plates were incubated
(at 371C, 5% CO2) for 45–60 minutes. Compound treatments were
given for 48 hours and cells were allowed to invade in the 2-mm
invasion zone created by Oris cell seeding stoppers. The cells were
stained with Calcein AM according to the manufacturer’s instructions.
Micrographs were captured using  4 magnification of inverted
Olympus IX71 (Olympus UK Ltd., Southend-on-Sea, UK) microscopy.
Invaded cells in the invasion zone were counted from four indepen-
dent experiments and average invaded cells were plotted on the
graphs.
Please see Supplementary data online for methodology used in this
study.
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